Last reviewed · How we verify
NCT06215495
A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
NA trial testing reduced target volume in Radiation Toxicity in 88 participants. Currently enrolling.
28 May 2027
Quick facts
| Lead sponsor | Zhujiang Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 88 |
| Start date | 18 February 2024 |
| Primary completion | 28 May 2027 |
| Estimated completion | 1 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- reduced target volume
- EORTC (European organisation for research and treatment of cancer) target volume
Conditions studied
- Radiation Toxicity — all drugs for Radiation Toxicity →
- MRI Simulated Positioning — all drugs for MRI Simulated Positioning →
- High Grade Glioma — all drugs for High Grade Glioma →
- Progression-free Survival — all drugs for Progression-free Survival →
Sponsor
Zhujiang Hospital
Who can join
Adults 18 to 65, any sex, with Radiation Toxicity or MRI Simulated Positioning. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main question it aims to answer are: 1. whether the new target delineation scheme can improve Progression-free Survival 2. whether it can reduce the incidence of radiation complications in high-grade glioma patients. Participants in trial group will be performed radiotherapy of new target delineation method after the completion of the operation within 4-6 weeks., while participants in the control group be performed radiotherapy of EORTC(European organisation for research and treatment of cancer) target delineation method.Temozolomide 75 mg / ( m² · d ) will be given to both groups of patients during radiotherapy. After radiotherapy, its dose changes to 150 \~ 200 mg / ( m² · d ) for 5 days and stopped for 23 days as a cycle. There are 6 cycles in total.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06215495
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiation Toxicity
Currently open trials in the same condition.
- NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
- NCT06311968 — The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor · Phase 2 · recruiting
- NCT05530655 — A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy · EARLY_PHASE1 · recruiting
- NCT06033183 — Integrative Molecular Analysis of Individual Radiosensitivity in Pediatric Oncology · NA · recruiting
- NCT06531681 — Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac) · recruiting
Other Zhujiang Hospital trials
Trials by the same sponsor.
- NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
- NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
- NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
- NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
- NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06215495 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06215495.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing